TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Not Specified
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Regeneron and Tessera Therapeutics announced a global collaboration to develop TSRA-196, a potential one-time gene editing treatment for Alpha-1 Antitrypsin Deficiency, with Tessera receiving $150 million upfront and sharing development costs and future profits equally.

Insights
REGN   positive

Expanding genetic medicine portfolio, partnering with innovative biotech company, demonstrating leadership in developing transformative treatments